GSK Says Incidence of Heart Attack With Avandia Same as With Placebo

Drug Industry Daily
A A
GlaxoSmithKline (GSK) has sent a letter to the editor of The Lancet describing safety data on Avandia that challenges a study published last week in the New England Journal of Medicine (NEJM) that said the diabetes drug increased the risk of heart attack and death.

To View This Article:

Login

Subscribe To Drug Industry Daily

Buy This Article Now

Add this article to your cart for $0.00